Bristol Myers Squibb’s Q2 earnings report showed its revenue grew 9% year-over-year.
Sanofi is benefiting from the continued success of its blockbuster asthma drug, Dupixent, which showed 29% sales growth in Q2.
Group forecasting full-year organic growth of 1%, a downgrade on its previous forecast.
Abbvie’s U.S. earnings were up 3.6% totalling $11.1 billion, international revenue also increased 6.8% to a total of $3.3 billion.
Both drugmakers enjoyed strong quarters and are forecasting higher results for the second half of 2024.
The PR agencies in Interpublic Group’s Specialized Communications and Experiential Solutions segment saw “solid” single-digit growth on an organic basis in the period.
Looking to the second half of the year, Thermo Fisher raised its full-year revenue to a range of $42.4 billion to $43.4 billion.
Publicis Groupe’s organic growth rate was 5.6% in Q2 2024.
Abbott attributed its growth to newly launched products, specifically its cardio-related products.
Looking forward, Novartis raised its full-year guidance for core operating income to a range from mid- to high teens.
Get the most out of
Register for free and enjoy unlimited access to: